LS
NBIX icon

Livforsakringsbolaget Skandia’s Neurocrine Biosciences NBIX Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Buy
18,500
+17,500
+1,750% +$2.6M 0.1% 115
2026
Q1 		$132K Hold
1,000
– – 0.01% 390
2025
Q4 		$142K Hold
1,000
– – 0.01% 405
2025
Q3 		$140K Hold
1,000
– – 0.01% 429
2025
Q2 		$126K Hold
1,000
– – 0.01% 461
2025
Q1 		$111K Hold
1,000
– – 0.01% 488
2024
Q4 		$137K Sell
1,000
-2,800
-74% -$346K 0.01% 462
2024
Q3 		$437K Buy
3,800
+800
+27% +$110K 0.02% 297
2024
Q2 		$413K Hold
3,000
– – 0.03% 203
2024
Q1 		$413K Hold
3,000
– – 0.04% 206
2023
Q4 		$395K Buy
3,000
+1,100
+58% +$127K 0.04% 207
2023
Q3 		$214K Hold
1,900
– – 0.02% 229
2023
Q2 		$179K Hold
1,900
– – 0.02% 240
2023
Q1 		$192K Hold
1,900
– – 0.02% 244
2022
Q4 		$227K Hold
1,900
– – 0.03% 241
2022
Q3 		$201K Sell
1,900
-600
-24% -$60.9K 0.02% 246
2022
Q2 		$244K Sell
2,500
-400
-14% -$36.9K 0.02% 307
2022
Q1 		$272K Hold
2,900
– – 0.02% 399
2021
Q4 		$247K Buy
2,900
+1,700
+142% +$156K 0.02% 454
2021
Q3 		$115K Hold
1,200
– – 0.01% 582
2021
Q2 		$117K Hold
1,200
– – 0.01% 599
2021
Q1 		$117K Hold
1,200
– – 0.01% 575
2020
Q4 		$115K Hold
1,200
– – 0.01% 564
2020
Q3 		$115K Hold
1,200
– – 0.01% 509
2020
Q2 		$146K Buy
1,200
+500
+71% +$55.3K 0.02% 440
2020
Q1 		$61K Hold
700
– – 0.01% 572
2019
Q4 		$75K Buy
+700
New +$73.3K 0.01% 579

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Livforsakringsbolaget Skandia's NBIX Position: Q2 2026 in Review

Livforsakringsbolaget Skandia increased its Neurocrine Biosciences (NBIX) stake by 1,750% in Q2 2026, buying an estimated $2.6M and bringing the position to 18,500 shares worth $3.12M. The position accounts for 0.1% of the portfolio, ranked #115.

Livforsakringsbolaget Skandia first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Livforsakringsbolaget Skandia held 18,500 shares of Neurocrine Biosciences worth $3.12M as of Q2 2026.
  • Livforsakringsbolaget Skandia bought 17,500 Neurocrine Biosciences shares in Q2 2026, an estimated $2.6M.
  • Neurocrine Biosciences made up 0.1% of Livforsakringsbolaget Skandia's portfolio in Q2 2026, its #115 holding.
  • Livforsakringsbolaget Skandia first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Livforsakringsbolaget Skandia's 13F filing for Q2 2026, filed 18 Aug 2026.